Pediatric Smoflipid Therapy: Patient Response and Safety Concerns

Background Intestinal failure–associated liver disease (IFALD) occurs in ≤85% of neonates receiving prolonged parenteral nutrition. Strategies for treatment of IFALD include alternative lipid therapies, such as Smoflipid (Fresenius Kabi). In this study, we reviewed our institutional Smoflipid use, including predictors of patient response and safety concerns. Methods This is a retrospective chart review of all pediatric patients who received...